Mayne Pharma Group (MYX) Q1 2027 TU earnings summary

Executive summary

• Q1 FY27 revenue was A$95.7m, down 2% YoY; gross margin was 63%, while underlying EBITDA was A$5.3m, down 52% YoY.

• Women's Health prescription growth and International expansion were offset by anticipated Dermatology erosion; management is prioritising Women's Health, DistributeRx and International growth.

• DistributeRx delivered 84k prescriptions, up 120% YoY, and expanded its prescriber base to 6,059 unique prescribers.

Financial highlights

• Revenue was A$95.7m, down A$2.0m or 2% YoY; gross profit was A$60.3m, down A$5.0m or 8% YoY.

• Direct contribution was A$23.3m, down 23% YoY; underlying EBITDA was A$5.3m, down 52% YoY.

• Reported EBITDA was a A$1.6m loss after A$6.9m of excluded non-recurring items, mainly A$6.0m legal costs and A$0.9m restructuring costs.

• Adjusted operating cash flow from continuing operations was an outflow of A$2.1m; cash and marketable securities were A$67.3m at 30 September 2026.

• Cash outflow reflected timing of gross-to-net rebate and chargeback payments; additional quarter outflows included A$3.5m royalties and A$4.5m legal costs.

Outlook and guidance

• Women's Health plans to accelerate growth through focused sales coverage, refreshed marketing and improved prescriber access, supported by removal of the HRT black-box warning.

• DistributeRx plans to scale across additional products and therapeutic areas, using established infrastructure.

• International priorities include building NEXTSTELLIS growth after PBS listing and leveraging the Salisbury investment for export and contract manufacturing revenue.

• Management will evaluate capital-efficient, synergistic acquisitions and maintain disciplined capital management.

• Lexington facility operations are expected to begin in early 2027; BLISSEL launch in Australia is targeted for FY28.